Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2013-10-17
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-10-31 (study day 15.0); relationship: POSSIBLE
moderate
assessed
Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-10-31 (study day 15.0); relationship: POSSIBLE
mild
assessed
Mild SOMNOLENCE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-22 (study day 37.0); relationship: REMOTE
moderate
assessed
Moderate SOMNOLENCE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-22 (study day 37.0); relationship: REMOTE
Data queries
No data queries.